SCHEMBL7735835

SCHEMBL7735835

CCCCn1ccc(-c2cc(OC)ccc2OCc2ccccc2)c(C(N)=O)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.43
MTNR1B P49286 2/20 0.41
TLR4 O00206 1/20 0.41
TLR3 O15455 1/20 0.41
TLR5 O60602 1/20 0.41
TLR2 O60603 1/20 0.41
CAMK2B Q13554 1/20 0.41
CAMK2G Q13555 1/20 0.41
CAMK2D Q13557 1/20 0.41
CAMK1 Q14012 1/20 0.41
CAMK4 Q16566 1/20 0.41
PNCK Q6P2M8 1/20 0.41
CAMK1D Q8IU85 1/20 0.41
CAMK1G Q96NX5 1/20 0.41
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
CAMK2A Q9UQM7 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
C5AR1 P21730 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7736090 0.87 TLR4 (0.43) MTNR1AMTNR1BTLR4TLR3TLR5
SCHEMBL7726010 0.85 TOP1 (0.41) MTNR1ATP53MAPTNPC1HPGD
SCHEMBL7736093 0.80 KDM4E (0.47) MTNR1AMTNR1BHDAC8MAPTNPC1
SCHEMBL7735544 0.80 EDNRA (0.41) MAOBMAPK14
SCHEMBL7734365 0.79 ICMT (0.45) TLR8MAPTKDM4E
SCHEMBL7726016 0.75 EDNRA (0.42) MAOBMAPK14
SCHEMBL7725867 0.72 LPAR1 (0.42)
SCHEMBL7737859 0.72 MEN1 (0.45) TLR8HPGDKDM4EHSD17B10
SCHEMBL7735824 0.70 GRM2 (0.49) MTNR1AMTNR1BTLR8KDM4EHSD17B10
SCHEMBL20382949 0.70 MAPK14 (0.50) TLR4TLR3TLR5TLR2CAMK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK MTNR1A 4038/4885MTNR1B 3794/4885TLR4 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.